arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

NEOGEN CORP

NEOG
$11.68 ▼ -0.78 (-6.26%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

NEOGEN CORP faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5B
Dividend Yield —
Revenue Growth 6.5% ↗
Op. Margin -0.8% ↘
ROIC -0.1% ↘
FCF / Share $0.06
Trailing P/E —
Price / Book 1.2x
FCF Yield 0.5%
Debt / Equity 0.37
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$222.80M
↑ +6.5% —
Net Income Profit after all expenses
$-11.90M
↓ -5.3% —
Operating Margin Operating profit as % of sales
-0.8%
↓ -158.7% 20th
FCF / Share Free cash flow per share
$0.06
↑ +18.4% —
Long-Term Debt Long-term obligations
$774.20M
↓ -2.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
35
Returns
41
Financial Health ↑
48
Cash Quality
3

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 67 quarters